• LAST PRICE
    7.9800
  • TODAY'S CHANGE (%)
    Trending Up0.0100 (0.1255%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    7.7704 / 7.9700
  • Day Range
    Low 7.7500
    High 7.9800
  • 52 Week Range
    Low 7.7500
    High 14.6800
  • Volume
    10,939
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 7.97
TimeVolumeCSBR
09:55 ET5257.7704
11:23 ET5007.7707
11:32 ET1007.75
11:38 ET2007.76
12:37 ET5007.85
01:09 ET15007.8946
01:22 ET1007.86
01:33 ET5007.8595
01:38 ET1007.87
01:45 ET4007.85
01:47 ET1007.87
02:27 ET1947.94
02:34 ET3337.97
02:36 ET40007.8801
02:56 ET1007.88
03:10 ET1007.915
03:12 ET1007.93
03:24 ET3007.94
03:28 ET1007.94
03:33 ET1007.96
03:57 ET2007.98
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCSBR
Champions Oncology Inc
107.8M
301.5x
---
United StatesBFRA
Biofrontera AG
78.1M
-4.1x
---
United StatesLJPC
La Jolla Pharmaceutical Co
125.2M
14.1x
---
United StatesOPNT
Opiant Pharmaceuticals Inc
121.0M
528.7x
---
United StatesNERV
Minerva Neurosciences Inc
36.0M
-1.0x
---
United StatesFREQ
Frequency Therapeutics Inc
166.8M
-2.2x
---
As of 2022-01-22

Company Information

Champions Oncology, Inc. is engaged in creating transformative technology solutions to be utilized in oncology drug discovery and development. This technology includes the Company’s in-vivo, ex-vivo and biomarker platforms, oncology software solutions, and computational-based discovery platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology. The Company’s software as a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. The Company’s drug discovery and development business leverages the computational and experimental capabilities within its platforms. Their discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify novel therapeutic targets.

Contact Information

Headquarters
855 N Wolfe St Ste 619BALTIMORE, MD, United States 21205-1511
Phone
410-369-0365
Fax
302-636-5454

Executives

Non-Executive Independent Chairman of the Board
Joel Ackerman
Chief Executive Officer, Director
Ronnie Morris
Chief Financial Officer
David Miller
Lead Independent Director
David Sidransky
Director
Robert Brainin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$107.8M
Revenue (TTM)
$44.4M
Shares Outstanding
13.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.98
EPS
$0.03
Book Value
$0.55
P/E Ratio
301.5x
Price/Sales (TTM)
2.4
Price/Cash Flow (TTM)
65.2x
Operating Margin
0.95%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.